看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
|# ? J1 s' [8 U& f& U% U$ m0 a* A& t! q! ?
0 l9 _& x* ~) b7 S- w5 W( p; x/ N# C
Currently available feasibility data for possible combination strategies.
, _5 ~8 @) T+ g- T( s————————————————————————————————
3 M+ Z/ c6 l& q3 JCombination Feasibility according to preliminary data
: b' I, s5 s: ]' k; y/ w4 b* u——————————————————————————————————( G- k' T: a6 h; Z( W
Bevacizumab + sorafenib Yes, reduced dose
6 ~% Q& C2 c3 U( S' w# j, V2 p& [Bevacizumab + sunitinib† No
. J! y: v. J) {Bevacizumab + temsirolimus Yes
2 T9 y( i, c, u5 H dBevacizumab + everolimus Yes
4 q; H7 J- }5 V3 ~1 eSorafenib + sunitinib ?
4 j) ~1 Q" a+ y+ M* e; \8 FSorafenib + temsirolimus Yes, reduced dose % M+ B) `8 V; f( f9 H' P* w
Sorafenib + everolimus Yes, reduced dose ' V/ l5 c% ^7 ]3 y! D! v, \
Sunitinib + temsirolimus† No 8 `# y2 M. @5 N' h- i/ z" |
Sunitinib + everolimus ?
5 |4 `9 D1 N, z" g: y& FTemsirolimus + everolimus ? , R* y G0 x9 _" I- S0 [0 d
————————————————————
; v: c1 ^0 j$ M†Led to US FDA warning.
9 D: {6 G/ X1 Q3 g7 N?: As yet unattempted combination.( ^# g7 U$ k; X9 _# R6 }& p! ]
|